All Journal Entries Journals

azithromycin for syphilis

May 18, 2010 - 0 comments
Tags:

syphilis

,

syphilis treatment

,

azithromycin



I thought perhaps many posters would find this abstract helpful.  http://www.ncbi.nlm.nih.gov/pubmed/20402591  Our own Dr Hook from the std expert forum co authored this study.  Turns out the 1 time dose of azithromycin most of us are given for chlamydia treatment is also covering syphilis which is very good news since we can't test for syphilis as early as chlamydia and gonorrhea.  For those who have a fear of needles this is also good news :)

J Infect Dis. 2010 Jun 1;201(11):1729-35.
A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.

Hook EW 3rd, Behets F, Van Damme K, Ravelomanana N, Leone P, Sena AC, Martin D, Langley C, McNeil L, Wolff M.



BACKGROUND: Syphilis remains an important source of morbidity worldwide. Long-acting penicillin is the only therapy currently recommended for syphilis in much of the world. Because of hesitation to use penicillin for fear of anaphylaxis, there is a need for an effective, well-tolerated alternative to penicillin for syphilis therapy.

METHODS: This multicenter, randomized clinical trial was conducted in clinics for the treatment of persons with sexually transmitted diseases. We compared serological cure rates for human immunodeficiency virus (HIV)-negative persons with early syphilis treated with azithromycin at a dosage of 2.0 g administered orally as a single dose with cure rates for those treated with benzathine penicillin G at a dosage of 2.4 million units administered intramuscularly.

RESULTS: A total of 517 participants were enrolled in the trial. In the intention-to-treat analysis, after 6 months of follow-up, serological cure was observed in 180 (77.6%) of 232 azithromycin recipients and 186 (78.5%) of 237 penicillin recipients (1-sided lower bound 95% confidence interval, 7.2%). Nonserious adverse events were more common among azithromycin recipients than they were among penicillin recipients (61.5% vs 46.3%), and such adverse events were accounted for, in large part, by self-limited gastrointestinal complaints. CONCLUSIONS: In this trial, the efficacy of azithromycin at a dosage of 2.0 g administered orally was equivalent to that of benzathine penicillin G for the treatment of early syphilis in persons without HIV infection.

Post a Comment